ReviewCurrent opinion in immunology2020
A three course menu for ILC and bystander T cell activation.
Review in Current opinion in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- PGE2 Enhances Human ILC3 Function but Constrains ILC2-to-ILC3 Plasticity.European journal of immunology · 2026Article
- IL-9 Is Essential for ILC2-Mediated but Not Th2- and Th17-Cell-Mediated Allergic Airway Inflammation in Mice.European journal of immunology · 2026Article
- Innate lymphoid cells: unsung heroes or villains in multiple sclerosis pathogenesis?Immunologic research · 2026Review
- Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation.Nature immunology · 2025Article
- Sensing of Liver-Derived Nicotinamide by Intestinal Group 2 Innate Lymphoid Cells Links Liver Cirrhosis and Ulcerative Colitis Susceptibility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- New insights into the function of Interleukin-25 in disease pathogenesis.Biomarker research · 2023Review
- Initiation of type 2 immunity at barrier surfaces.Mucosal immunology · 2023Review
- Distinct regulatory machineries underlying divergent chromatin landscapes distinguish innate lymphoid cells from T helper cells.Frontiers in immunology · 2023Article
- Antiviral Activities of Group I Innate Lymphoid Cells.Journal of molecular biology · 2022Review
- Heartbreakers or Healers? Innate Lymphoid Cells in Cardiovascular Disease and Obesity.Frontiers in immunology · 2022Review
- Type 2 immunity in intestinal homeostasis and inflammatory bowel disease.Biochemical Society transactions · 2021Review
- Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells.Cancer research · 2021Article
- Immune System Investigation Using Parasitic Helminths.Annual review of immunology · 2021Review
- Maintenance of Barrier Tissue Integrity by Unconventional Lymphocytes.Frontiers in immunology · 2021Review
- Multi-Dimensional Gene Regulation in Innate and Adaptive Lymphocytes: A View From Regulomes.Frontiers in immunology · 2021Review
- Bystander CD4Experimental & molecular medicine · 2020Review
- Tuft-Cell-Derived Leukotrienes Drive Rapid Anti-helminth Immunity in the Small Intestine but Are Dispensable for Anti-protist Immunity.Immunity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The varied list of agonists that activate innate lymphoid cells (ILCs) continues to grow, but whether and how these signals interact is not well defined, especially in vivo. ILC subsets share master transcription factors, chromatin landscapes, and effector cytokines with their corresponding T helper (Th) cell subsets. Here we discuss how studies of these two cell types can inform each other. Specifically, we outline a framework in which ILC agonists are grouped by the transcription factors they activate. Optimal ILC activation requires at least three items from a 'menu' of non-redundant signals that collectively replicate the STAT and TCR signaling that drives effector Th cell function. This conceptual model may also apply to TCR-independent 'bystander' activation of Th cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.